Article thumbnail

Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy1

By Rukmini Rajagopalan, David Laitinen and Birgitta Dietz

Abstract

Metabolic and morphological side-effects occur in HIV-infected individuals receiving anti-retroviral treatment (ART). Peripheral fat loss that occurs particularly in the face, limbs and/or buttocks is referred to as lipoatrophy and has been found to be highly stigmatizing and to adversely impact the health-related quality of life (HRQL). Consumer Health Sciences Survey data collected between November 2003 and January 2006 were utilized to evaluate the impact of lipoatrophy on the HRQL in HIV-infected individuals receiving ART. This was evaluated using analysis of variance with item scores and mental component summary (MCS) and physical component summary (PCS) scores from the Medical Outcomes Trust questionnaire, SF-8 as dependent variables and lipoatrophy as the independent variable controlling for baseline age, sex and ethnicity. Clinical meaningfulness (mean difference divided by population standard deviation, δ/σ) of differences between the groups with and without lipoatrophy was also evaluated. A cohort of 1124 subjects with at least six months of ART was selected based on the availability of data on whether or not lipoatrophy was present. Subjects were primarily male (80%), between the ages of 30 and 60 years (90%), Hispanic (37%) and about 25% each of African American and White. Overall, prevalence of lipoatrophy in this cohort of HIV patients was 18.9%. Statistically significant (p < 0.001) differences in quality of life (as measured by SF-8 individual item scores and MCS and PCS scores) were observed between the two groups. The differences between the groups in item and summary scores were clinically meaningful in the small to near medium range (0.28–0.43). HIV-infected patients already experience a considerable deficiency in HRQL compared to general population; this study demonstrates that lipoatrophy further enhances that negative impact on HRQL

Topics: Research Article
Publisher: Taylor & Francis
OAI identifier: oai:pubmedcentral.nih.gov:3320100
Provided by: PubMed Central

Suggested articles

Citations

  1. (2002). (for the DAGNA ¨ Lipantiretroviral therapy study group).
  2. (2003). A qualitative study of the psychosocial implications of lipodystrohy syndrome on HIV-positive individuals.
  3. (2006). A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
  4. (2002). Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV cohort study.
  5. (2002). Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection.
  6. (2006). Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution.
  7. (2005). Beyond efficacy: Impact of combination antiretroviral therapy on quality of life.
  8. (2001). How to score and interpret Single-Item Health Status Measures. A manual for users of the SF-8 TM Health Survey.
  9. (2003). Limitations in HIV therapies: Opportunities for improvement.
  10. (2007). Metabolic outcomes of ACTG 5142: A prospective, randomized Phase III trial of NRTI-, PIand NNRTI-sparing Regimens for initial treatment of
  11. (2003). Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy.
  12. (2003). Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART.
  13. (2002). Relationship between HAART adherence and adipose tissue alterations.
  14. (1998). Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey.
  15. (2005). Self-perception of body changes in persons living with HIV/AIDS: Prevalence and associated factors.
  16. (1988). Statistical power analysis for the behavioral sciences
  17. (2004). What is HIV-associated lipodystrophy? Defining fat distribution changes

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.